Manage Future Cancer Risk, Inform Treatment Decisions Related to PARP Inhibitors1-4

Sources:

  1. Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533
  2. Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560).
  3. Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566).
  4. Pujade-Lauraine et al. Lancet Oncol (2017). ttp://dx.doi.org/10.1016/S1470-2045(17)30469-2